Advancing Cancer Treatments with Avastin® in Clinical Trials
Avastin® (Bevacizumab) stands at the forefront of the battle against cancer, pioneering advancements in disease treatment. It frequently plays a vital role in clinical trials, as researchers seek new therapeutic approaches to conquer a diverse range of cancers.
Unlike chemotherapy which attacks cancer cells, Avastin® is designed to block the blood supply that feeds a tumour. It inhibits angiogenesis, preventing the growth of new blood vessels, which tumours need in order to grow. It does this by targeting a protein called vascular endothelial growth factor (VEGF). VEGF is naturally produced in the body by normal cells, but certain cancer cells overproduce it. The blockade of VEGF can hinder the development of both regular blood vessels and those that nourish tumours, potentially curtailing their growth.
Often used in conjunction with other treatments, Avastin® is provided to the patient as an infusion and can be used on the following cancers:
- Metastatic Colorectal Cancer (mCRC)
- Non–Small Cell Lung Cancer (nsNSCLC)
- Glioblastoma (GBM)
- Metastatic Kidney Cancer (mRCC)
- Advanced Cervical Cancer (CC)
- Ovarian Cancer (OC)
- Hepatocellular Carcinoma (HCC)
Secure the Best Avastin® Price for Clinical Trials
Obtaining the best price for medicines is an essential part of budgeting for any clinical trial. With increased demand comes increased price.
For clinical trials, Oximio can offer Avastin®, supported with Certificate of Analysis (CoA) and EU Equivalency Statement. We can secure Avastin® in vial strengths of 100mg and 400mg with a minimum 18-month expiry date.
Please contact us today for a quotation for Avastin® for clinical trials. We would be delighted to provide you with our best prices.
At Oximio, we provided a complete start to finish logistics service for clinical trials. Further information on our full range of comparator sourcing services can be found on our website.